Introduction {#Sec1}
============

Several randomized trials of trastuzumab (TZM) have demonstrated improved outcomes in patients with HER2-positive early breast cancer (EBC) \[[@CR1]--[@CR4]\]. We previously conducted the JBCRG C-01 cohort study, and reported the efficacy and safety of perioperative trastuzumab therapy for HER2-positive EBC \[[@CR5]\]. However, the long-term outcomes are not yet clear. Recently, perioperative therapy for HER2-positive EBC has been improved via attempts to eliminate anthracycline \[[@CR1], [@CR6], [@CR7]\], the development of anti-HER2 agents, such as neratinib \[[@CR8]\] and pertuzumab \[[@CR9]\], and shortening of the trastuzumab administration duration \[[@CR10]--[@CR12]\]. The current issue is to distinguish patients who require more potent treatment from those for whom administration must be de-escalated. Furthermore, due to the increased options for post-recurrence treatment \[[@CR13], [@CR14]\], there is a growing need to carry out surveillance for recurrence on an appropriate schedule. In this study, the effectiveness of TZM therapy as perioperative therapy for HER2-positive operable breast cancer in daily clinical practice was evaluated, and the clinical issues based on the updated data from the JBCRG C-01 study were examined.

Patients and study design {#Sec2}
=========================

An observational study was performed on patients aged over 20 years who were histologically diagnosed with invasive HER2-positive breast cancer stage I--III C and treated using TZM. Patients (*n* = 2024) from 56 institutions which participated in the Japan Breast Cancer Research Group (JBCRG) between July 2009 and June 2016 were registered in this study. All patients received perioperative TZM-containing therapy between January 2006 and June 2011 for at least 10 months. The data were finalized in August 2016. Forty-three patients who failed to meet the eligibility criteria were excluded and 1981 datasets were analyzed in this study.

The study protocol was approved by each institutional review board. We ensured that the subjects received a full explanation of the study according to the ethical guidelines for epidemiological studies and received their written informed consent or opt-out in accordance with the standards of the study centers. Data were managed by the Department of EBM Research, Institute for the Advancement of Clinical and Translational Science, Kyoto University Hospital, and the JBCRG Data Center. This study has been registered in the University Hospital Medical Information Network (UMIN), number UMIN000002737.

Primary and secondary endpoints {#Sec3}
-------------------------------

The endpoints in this study were previously described \[[@CR5]\]. In brief, the primary and secondary endpoints were disease-free survival (DFS) and overall survival (OS), respectively.

Statistics {#Sec4}
----------

The Kaplan--Meier method was used to estimate DFS and OS curves. The Chi-squared (*x*^2^) test or Wilcoxon tests for categorical data and log-rank test for time-to-event endpoints provided two-sided *p* values, and a *p* value \< 0.05 was considered significant. Cox regression analysis was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Covariates used in the multivariate model were age, clinical tumor stage, clinical nodal stage, estrogen receptor (ER)/progesterone receptor (PgR) status, HER2 status, histological/nuclear grade, menopausal status, and past medical history. Statistical analyses were performed using SAS ver. 9.2 (SAS Institute).

Results {#Sec5}
=======

Patient characteristics and treatment {#Sec6}
-------------------------------------

The median follow-up period was 80.9 (5.0--132.2, mean 80.2) months. Baseline characteristics and treatments are summarized in Table [1](#Tab1){ref-type="table"}. The expression of ER, PgR, and HER2, and grade were determined using biopsy specimens before preoperative treatment from patients who received preoperative therapy or surgical specimens from patients without preoperative therapy.Table 1Patient characteristics and treatmentNumber(%)Total1981100.0Age \< 35703.5 35--4955428.0 50--5971336.0 60--6950125.3 ≥ 701437.2 Mean, SD54.310.7 Max, Min1886Menopausal state Premenopause69835.2 Postmenopause128364.8Tumor stage at initial diagnosis TX50.3 Tis271.4 T080.4 T163732.2 T2103052.0 T31728.7 T41025.1Nodal status at initial diagnosis NX40.2 N0113157.1 N167334.0 N21306.6 N3422.1 NA10.1Tumor grade 11799.8 263334.5 3102155.7 NA1487.4ER/PgR status ER and/or PgR positive89545.9 ER and PgR negative105754.1 NA291.5HER2 status IHC 3161784.0 IHC ≤ 2 FISH+26413.7 FISH +432.2 Not classified above572.9Neoadjuvant therapy performed70235.4Adjuvant therapy performed197499.6Trastuzumab administration Preoperative only261.3 Pre- and postoperative44022.2 Postoperative only151576.5Hormonal therapy performed95448.2Surgery95448.2 Partial mastectomy102151.6 Mastectomy95948.4 NA10.1Radiotherapy performed113957.5*LN* lymph node, *ER* estrogen receptor, *PgR* progesterone receptor, *IHC* immunohistochemical staining, *FISH* fluorescence in situ hybridization, *NA* not available

Mastectomy was performed for 959 patients and breast-conserving surgery for 1021 patients. A total of 1139 patients received postoperative radiotherapy and 954 patients received postoperative hormonal therapy.

In this observational study assessing the common use of TZM, we did not predetermine the treatment protocol. In brief, of the 702 patients who received preoperative therapy, 415 received TZM preoperatively and 26 received only TZM preoperatively. A total of 1279 patients received postoperative systemic therapy only, and 137 patients received TZM monotherapy (Table [2](#Tab2){ref-type="table"}).Table 2Systemic treatment (in detail)*CTx* chemotherapy, *A* anthracycline, *T* taxane

DFS and OS {#Sec7}
----------

The 5- and 10-year DFS rates were 88.9 (95% CI 87.5--90.3%) and 82.4% (95% CI 79.2--85.6%), respectively. The 5- and 10-year OS rates were 96% (95% CI 95.1--96.9%) and 92.7% (95% CI 91.1--94.3%), respectively (Fig. [1](#Fig1){ref-type="fig"}a, b).Fig. 1**a** Disease-free survival (DFS) for all patients. **b** Overall survival (OS) for all patients

Timing of recurrence with respect to organs {#Sec8}
-------------------------------------------

We calculated the annual risk of first recurrence with respect to ER expression and sites (Fig. [2](#Fig2){ref-type="fig"}a--f). ER-negative disease often recurred earlier than ER-positive disease. With respect to the site of the first recurrence, the incidence of liver and lung metastasis reached a peak at 2--3 years after surgery. However, there was no peak in thoracic wall, supraclavicular, or parasternal lymph node recurrence after surgery, and a relatively high recurrence rate was continuously observed in a relatively late phase (5--7 years). The peak of brain metastasis was 1 year earlier than that of liver metastasis.

Analysis of factors influencing DFS and a recurrence model {#Sec9}
----------------------------------------------------------

Univariate analyses comparing subgroups were performed using the log**-**rank test; hazard ratios (HRs) with 95% CIs were derived from Cox proportional hazards models (Table [3](#Tab3){ref-type="table"}).Table 3Univariate analysisUnivariate analysisBSEHR (95% CI upper, lower)*p* valueAge Per year, continuous0.0120.0061.0121.000, 1.0230.044  \< 60 vs. ≥ 600.3170.1241.3731.077, 1.7500.011  \< 70 vs. ≥ 700.7450.1832.1071.471, 3.019\< 0.001Menopausal status Pre- vs. post-menopause0.0410.1271.0420.812, 1.3370.746T stage T1 vs. T2-40.9500.1622.5861.884, 3.552\< 0.001N sage N0 vs. N1-30.8930.1252.4441.912, 3.123\< 0.001Pathological tumor size ≤ 1 cm vs. \> 1 cm0.3830.1421.4671.110, 1.9380.007Pathological lymph node metastasis 0 vs. 1--3 lymph nodes involved0.4290.1451.5361.156, 2.0430.003 0 vs. ≥ 4 lymph nodes involved1.1520.1493.1642.365, 4.233\< 0.001 pN0 vs. pN + 0.7150.1212.0441.611, 2.594\< 0.001Grade Grade 1 vs. 2− 0.0850.2240.9180.592, 1.4240.703 Grade 1 vs. 3− 0.0360.2130.9640.6350.865ER status Negative vs. positive− 0.1040.1230.9010.708, 1.1460.396HER2 status IHC 3 + vs. 2 + FISH + − 0.0230.1800.9770.687, 1.3890.896 IHC 3 + vs. FISH + 0.3210.3601.3780.681, 2.7900.373Surgery (type) Partial vs. total mastectomy0.4860.1231.6261.278, 2.070\< 0.001Preoperative systemic therapy No vs. Yes0.4090.1221.5051.185, 1.9120.001 CTx concurrent with TZM vs. sequential0.1960.4251.2170.529, 2.8020.644 CTx concurrent with TZM vs. without CTx− 9.998230.8410.0000.000, inf0.965Postoperative systemic therapy No vs. yes− 1.9560.5040.1410.053, 0.380\< 0.001 CTx concurrent with TZM vs. sequential− 0.0060.1820.9940.696, 1.4190.974 CTx concurrent with TZM vs. without CTx0.4720.1761.6041.136, 2.2630.007Chemotherapy No vs. yes (pre and/or postoperative)− 0.3800.2060.6840.457, .0250.066*B* regression coefficient, *SE* regression coefficient of regression coefficient, *HR* hazard ratio; *95% CI* 95% confidence interval

Multivariate analysis revealed the risk factors for recurrence to be an age of ≥ 70 years, T2 or larger tumors, clinically detected lymph node metastasis, histological tumor diameter of \> 1 cm, histologically detected lymph node metastasis(≥ n2), and the implementation of preoperative treatment. We prepared the risk score of recurrence based on the results of the multivariate analysis. When comparing the compulsive insertion method with the variable-increasing method using likelihoods, significant factors remained. Based on the coefficient calculated, the score ratio was calculated and the final score was determined by rounding off the values (Table [4](#Tab4){ref-type="table"}). We calculated the 5-year recurrence risk for each total point (Table [5](#Tab5){ref-type="table"}) and estimated the Kaplan--Meier curve for the DFS of each score (Fig. [3](#Fig3){ref-type="fig"}). The C-index was 0.653.Table 4Multivariate analysis and risk scoreMultivariate Model 1: Compulsive insertion methodMultivariate Model 2: Variable-increasing method using likelihoodsScore ratioScore (point)BSEHRHR (95% CI upper lower)*p* valueBSEHRHR (95% CI upper lower)*p* valueAge \< 70RefRef ≥ 700.8500.1912.3401.6103.400\< 0.0010.8500.1912.3401.6103.400\< 0.0012.1932Tumor stage T1RefRef T2--40.5840.1751.7931.2732.5260.0010.5840.1751.7931.2732.5260.0011.5072 TX Tis T0− 0.0860.7260.9170.2213.8040.905−  0.0860.7260.9170.2213.8040.905Nodal status N0RefRef N1--30.3880.1621.4731.0732.0230.0160.3880.1621.4731.0732.0230.0161.0001 NX1.0531.0132.8660.39320.8830.2991.0531.0132.8660.39320.8830.299Tumor size (pathological) \< 1 cmRefRef ≥ 1 cm0.4850.1691.6231.1662.2600.0040.4850.1691.6231.1662.2600.0041.2501Lymph node metastasis n0RefRef n10.2240.1721.2510.8941.7520.1920.2240.1721.2510.8941.7520.192 n2--30.7800.1882.1821.5113.151\< 0.0010.7800.1882.1821.5113.151\< 0.0012.0132Preoperative systemic therapy NoRefRef Yes0.5700.1581.7691.2972.412\< 0.0010.5700.1581.7691.2972.412\< 0.0011.4721*B* regression coefficient, *SE* regression coefficient of regression coefficient, *HR* hazard ratio, *95% CI* 95% confidence interval, *ref* referenceTable 5Risk score and estimated 5-year recurrence risk for each total pointVariableRisk pointAge ≥ 702T stage T2--42N stage N1--31Tumor size (pathological) ≥ 1 cm1Lymph node metastasis (≥ n2)2Preoperative systemic therapy (yes)1Total scoreProbability (%)03.514.726.438.6411.6515.6621.1728.4838.4951.8Fig. 2Annual hazard of recurrence. **a** All. **b** Stratified by ER status. **c**--**h** Stratified by first recurrence site, **c** liver, **d** lung, **e** chest wall, supraclavicular lymph node, and para sternal lymph node, **f** brain, **g** bone, **h** ipsilateral breast and axillary lymph nodeFig. 3Estimated DFS of each score

Discussion {#Sec10}
==========

In Japan, perioperative treatment using trastuzumab has markedly improved the outcomes of HER2-positive breast cancer patients. Even with perioperative chemotherapy using anthracycline or taxanes, approximately 25% of patients with HER2-positive breast cancer developed recurrence before trastuzumab became commercially available \[[@CR15]\]. These results are consistent with those in the placebo group in a phase III clinical study of perioperative pertuzumab therapy (APHINITY study) \[[@CR9]\]. No new AEs related to TZM were detected in this study.

The present study had several limitations. This cohort study was a single-arm observational study of TZM with or without chemotherapy in daily practice; therefore, the treatment effectiveness and clinicopathological features, including HR and HER2 status, were assessed by physicians. Treatment selection by each physician, including the surgical procedure, radiotherapy, and chemotherapy, may have affected the outcomes. The need for chemotherapy, especially for patients over 70 years of age, was not significant in this study, but conclusions should be carefully held until results of a randomized study are available.

An age of ≥ 70 years, grade of T2 or higher, clinically detected lymph node metastasis, histological tumor diameter of ≥ 1 cm, and histologically detected lymph node metastasis were extracted as prognostic factors, similar to the previous report \[[@CR5]\]. Subgroup analysis in the APHINITY trial \[[@CR9]\] also demonstrated the additive effects of pertuzumab in patients with lymph node metastasis or elderly patients. In this analysis, our recurrence-predicting model included the clinical N stage and pathological node-positive status. When employing the variable-increasing method with the likelihood ratio as mutually independent factors on multivariate analysis, these two factors remained.

Furthermore, the significance of histological node-positive status (*n*) and pathological tumor size (*t*) were suggested to depend on the presence of preoperative treatment; therefore, an additional subgroup analysis regarding the presence of preoperative treatment was performed. There was no preoperative treatment-related difference in the values on DFS of *n* and *t* (Supplement 1). Furthermore, we directly investigated the interaction between the presence of preoperative treatment and lymph node metastasis or pathological tumor size by analysis involving an interaction item, but it was insignificant. The influence of lymph node metastasis or pathological tumor size on DFS may be similar regardless of the presence of preoperative treatment. Indeed, even if preoperative chemotherapy results in pn0, the risk of recurrence was higher than if it was N0 before the start of treatment (Supplement 2).

In the guidelines, regular imaging, such as CT, is not recommended for asymptomatic patients \[[@CR16]\]. In our study, the timing and annual risk of recurrent HER2-positive breast cancer were characterized by each organ. In particular, the start of treatment for recurrence in the phase of restricted tumor burden in patients with brain or bone metastases may minimize complications or treatment-related adverse effects. As the number of treatment options, such as pertuzumab \[[@CR13]\] and T-DM1 \[[@CR14]\], for metastatic or recurrent HER2-positive breast cancer has recently increased, this should be reflected in follow-up plans \[[@CR17]\].

Recently, perioperative therapy for HER2-positive EBC has been improved via attempts to eliminate anthracycline \[[@CR1], [@CR6], [@CR7]\], the development of anti-HER2 drugs with different actions, such as neratinib \[[@CR8]\] and pertuzumab \[[@CR9]\], and shortening of the trastuzumab administration period \[[@CR10], [@CR11]\]. If the risk of recurrence is high, the addition of pertuzumab or extension of neratinib treatment should be considered. Patients who fail to achieve pathological CR following neoadjuvant HER2-targeted therapy (along with chemotherapy) are also at increased risk for recurrence. For such patients, T-DM1 should be considered \[[@CR18]\]. On the other hand, if the risk is low, treatment using short-term trastuzumab therapy may be successful. To optimize such treatment, it is necessary to comprehensively understand the risk of recurrence. Although the current staging is based on clinicopathological characteristics, our findings suggest that host factors, such as age, are included. Our recurrence model may be useful for future studies after validation.

Conclusion {#Sec11}
==========

As this recurrence model was created based on the data from an observational study, validation is necessary. However, it may facilitate calculation of the risk of recurrence, thereby improving treatment selection.
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